Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release".
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs & Pharmaceuticals reported strong Q3 FY26 results with revenue of Rs 1,160 cr, up 14.8% year-on-year from Rs 1,010 cr. Adjusted EBITDA grew 21% YoY to Rs 147 cr, with margins expanding to 12.7% from 12.0% last year, driven by better capacity utilization and ramp-up of newer facilities. Adjusted PAT rose 29.5% YoY to Rs 86 cr, with margins improving to 7.2% from 6.5%. The CDMO business posted over 16% revenue growth on the back of double-digit volume increase, while the international branded formulation segment more than doubled sequentially on demand recovery. The company also secured EU GMP certification for two facilities (Oral Solids renewal and Oral Liquids grant) and received its first UK MHRA approval for Rivaroxaban tablets, strengthening its regulated markets presence.
Positive for shareholders — strong beat on both revenue and profitability with significant sequential margin expansion signals improving operational efficiency. Regulatory certifications and entry into UK markets expand the growth runway in high-value geographies, which could support re-rating of the stock.